
Laurus Labs ranks 5th by market capitalisation among 71 Pharmaceuticals companies tracked by ATS. Its largest peers are Sun Pharmaceutical Industries, Divi's Laboratories and Torrent Pharmaceuticals. Its P/E of 101.4 compares with a peer median of 33.6.
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,773.60 | -1.69% | 4,25,546 | 35.2 | 5.09 | 14.7% | +12.5% |
| Divi's Laboratories | 9,586.00 | +0.38% | 2,54,478 | 87.0 | 15.18 | 16.2% | +12.5% |
| Torrent Pharmaceuticals | 4,693.90 | -1.64% | 1,58,863 | 72.8 | 18.94 | 27.1% | +12.5% |
| Zydus Lifesciences | 1,151.30 | -0.71% | 1,15,848 | 25.7 | 4.27 | 19.7% | +12.5% |
| Laurus Labs | 2,052.90 | +0.14% | 1,10,827 | 101.4 | 20.91 | 18.2% | +22.0% |
| Cipla | 1,333.00 | -0.54% | 1,07,677 | 32.0 | 3.13 | 11.8% | +12.5% |
| Mankind Pharma | 2,496.00 | -0.16% | 1,03,042 | 50.4 | 6.32 | 12.5% | +12.5% |
| Dr. Reddy's Laboratories | 1,194.90 | -1.08% | 99,533 | 30.1 | 2.60 | 12.1% | +12.5% |
| Aurobindo Pharma | 1,677.90 | -0.88% | 97,453 | 26.3 | 2.57 | 9.9% | +12.5% |
| Lupin | 2,006.70 | -1.11% | 91,742 | 16.6 | 4.09 | 26.9% | +12.5% |
| Glenmark Pharmaceuticals | 2,286.10 | -1.08% | 64,514 | 35.9 | 6.14 | 14.1% | +12.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 7 October 2026. How this data is compiled.
Laurus Labs' listed peers in Pharmaceuticals include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences, Cipla and Mankind Pharma, ranked here by market capitalisation.
Laurus Labs trades at a P/E of 101.4, against a median of 33.6 across the 10 Pharmaceuticals peers shown.
By market capitalisation, the largest company in the group is Sun Pharmaceutical Industries at ₹4.26 lakh crore, against ₹1.11 lakh crore for Laurus Labs.
Track LAURUSLABS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.